| 1 |
35289517 | [Lipoprotein (a) :NSFA consensus]. | 2022 Feb |
1 |
| 2 |
35583875 | Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review. | 2022 May 18 |
1 |
| 3 |
35606071 | Existing and emerging strategies to lower Lipoprotein(a). | 2022 May |
1 |
| 4 |
33537217 | Recent Updates of Lipoprotein(a) and Cardiovascular Disease. | 2021 Jan |
1 |
| 5 |
33603500 | Novel Experimental Agents for the Treatment of Hypercholesterolemia. | 2021 |
1 |
| 6 |
33741767 | Contemporary perspectives on the genetics and clinical use of lipoprotein(a) in preventive cardiology. | 2021 May 1 |
1 |
| 7 |
33872986 | Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. | 2021 May |
3 |
| 8 |
34148150 | Genetics of Lipoprotein(a): Cardiovascular Disease and Future Therapy. | 2021 Jun 20 |
2 |
| 9 |
34232223 | The Role of Antisense Therapies Targeting Lipoprotein(a). | 2021 Jul 1 |
2 |
| 10 |
34235598 | Lipoprotein (a): When to Measure and How to Treat? | 2021 Jul 8 |
1 |
| 11 |
34356902 | Lipoprotein(a) Where Do We Stand? From the Physiopathology to Innovative Terapy. | 2021 Jul 19 |
1 |
| 12 |
34572458 | Modern Approaches to Lower Lipoprotein(a) Concentrations and Consequences for Cardiovascular Diseases. | 2021 Sep 20 |
1 |
| 13 |
34840125 | Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Société Francophone d'Athérosclérose (NSFA). | 2021 Dec |
3 |
| 14 |
31916186 | Potential of Lipoprotein(a)-Lowering Strategies in Treating Coronary Artery Disease. | 2020 Feb |
4 |
| 15 |
32011323 | Increased cardiovascular risk associated with hyperlipoproteinemia (a) and the challenges of current and future therapeutic possibilities. | 2020 Jan |
1 |
| 16 |
32277995 | What do we know about the role of lipoprotein(a) in atherogenesis 57 years after its discovery? | 2020 May - Jun |
1 |
| 17 |
32492513 | Lipid lowering therapy in cardiovascular disease: From myth to molecular reality. | 2020 Sep |
1 |
| 18 |
32635396 | Lipoprotein(a) Lowering-From Lipoprotein Apheresis to Antisense Oligonucleotide Approach. | 2020 Jul 3 |
1 |
| 19 |
32716473 | New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention. | 2020 Oct 1 |
1 |
| 20 |
30616181 | Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia. | 2019 Feb |
2 |
| 21 |
30838556 | Lipoprotein(a)-an interdisciplinary challenge. | 2019 Apr |
1 |
| 22 |
30847681 | Can Lp(a) Lowering Against Background Statin Therapy Really Reduce Cardiovascular Risk? | 2019 Mar 7 |
1 |
| 23 |
30859384 | Lipoprotein(a)-antisense therapy. | 2019 Apr |
1 |
| 24 |
30986377 | Biology, pathophysiology and current therapies that affect lipoprotein (a) levels. | 2019 Jun |
1 |
| 25 |
31061262 | Lipoprotein(a) as an Old and New Causal Risk Factor of Atherosclerotic Cardiovascular Disease. | 2019 Jul 1 |
2 |
| 26 |
31111240 | Antisense Oligonucleotides Targeting Lipoprotein(a). | 2019 May 20 |
7 |
| 27 |
31367887 | Lp(a): Addressing a Target for Cardiovascular Disease Prevention. | 2019 Jul 31 |
1 |
| 28 |
31655942 | Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives. | 2019 Dec |
2 |
| 29 |
29174389 | Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. | 2018 Jan - Feb |
1 |
| 30 |
29262744 | Lipoprotein(a) in clinical practice: New perspectives from basic and translational science. | 2018 Jan |
2 |
| 31 |
28078998 | Lipoprotein(a) Management: Pharmacological and Apheretic Treatment. | 2017 |
1 |
| 32 |
28128058 | Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)? | 2017 |
4 |
| 33 |
28814237 | Statins in Aortic Stenosis. | 2017 Aug 15 |
1 |
| 34 |
29096859 | Lipoprotein(a)-apheresis in the light of new drug developments. | 2017 Nov |
1 |
| 35 |
26538546 | Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. | 2016 Mar |
1 |
| 36 |
27665230 | Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. | 2016 Nov 5 |
1 |
| 37 |
25318824 | Latest developments in the treatment of lipoprotein (a). | 2014 Dec |
1 |
| 38 |
9799211 | Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression. | 1998 Nov 3 |
1 |
| 39 |
8962057 | Molecular cloning of a high-affinity receptor for the growth factor-like lipid mediator lysophosphatidic acid from Xenopus oocytes. | 1996 Dec 10 |
1 |
| 40 |
1970974 | Variation in the size of human apolipoprotein(a) is due to a hypervariable region in the gene. | 1990 May |
1 |